Search
Precipio Inc
PRPOAdd to Watchlist
25.260USD
+0.330+1.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
45.06MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.32%
5 Days
+8.37%
1 Month
+8.13%
6 Months
+6.05%
Year to Date
+9.92%
1 Year
+109.63%
Key Figures
25.293Open
25.365High
6.89KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.39%Turnover Ratio
24.930Prev. Close
22.760Low
72.66KTurnover
LossP/E Static
3.18P/B
0.00%Div Yield TTM
-4.78%ROA
33.63052wk High
0.61Volume Ratio
-4.29MNet Profit
1.78MShares
-0.4471EPS TTM
1.33Beta
-7.13%ROE
9.30052wk Low
10.45%Amplitude
40.60%Gross Margin
45.06MMarket Cap
1.53Reward/Risk
4.39%Risk Rate
TradingKey Stock Score of Precipio Inc
Currency: USD Updated: 2026-07-02Key Insights
Precipio Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precipio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Precipio Inc Highlights
StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.25% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.05M.
Undervalued
The company’s latest PE is -56.49, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 341.74K shares, decreasing 7.77% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Precipio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Precipio Inc Info
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEODanieli (Ilan S)
Websitehttps://www.precipiodx.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Precipio Inc (PRPO)?
The current price of Precipio Inc (PRPO) is 25.26.
What is the symbol of Precipio Inc?
The ticker symbol of Precipio Inc is PRPO.
What is the 52-week high of Precipio Inc?
The 52-week high of Precipio Inc is 33.63.
What is the 52-week low of Precipio Inc?
The 52-week low of Precipio Inc is 9.30.
What is the market capitalization of Precipio Inc?
The market capitalization of Precipio Inc is 45.06M.
What is the Earnings Per Share (EPS TTM) of Precipio Inc (PRPO)?
The Earnings Per Share (EPS TTM) of Precipio Inc (PRPO) is -0.23.